New International Guidelines Support Population-Wide Screening for Early-Stage Type 1 Diabetes

An international consensus statement endorsed by 20 health organizations, including the European Association for the Study of Diabetes and the International Society of Pediatric and Adolescent Diabetes, now recommends screening children in the general population for early-stage Type 1 diabetes. The guidance, developed by a writing panel convened by Breakthrough T1D, addresses how to identify people at risk before they develop symptoms.

This new guidance builds on a 2024 document that outlined how to care for people already identified through screening or family-member programs like TrialNet. Together, these two sets of recommendations form a comprehensive approach: first identifying people at risk, then monitoring and treating them appropriately.

One key reason for expanding screening beyond families is striking: approximately 85% of people diagnosed with Type 1 diabetes have no family history of the disease and no first-degree relatives with the condition. This means family-based screening alone will miss the majority of people who will eventually receive a Type 1 diabetes diagnosis.

Early detection through screening offers real benefits. Studies show that identifying people before they develop clinical symptoms reduces the likelihood of diabetic ketoacidosis (DKA)—a serious, potentially life-threatening complication that can occur at diagnosis. Early identification also gives people access to approved therapies and clinical trials designed to delay disease progression.

When screening identifies people with islet autoantibodies—markers that indicate early-stage Type 1 diabetes—confirmation testing using a second sample is recommended. People with a single autoantibody are at lower risk of progression than those with multiple autoantibodies, and monitoring plans are tailored accordingly.

The consensus guidance emphasizes that people identified through screening need regular medical monitoring, including periodic glucose assessments, education about diabetes symptoms and DKA warning signs, and psychosocial support. Much of this care can happen in primary care settings, but guidelines recommend fostering partnerships between endocrinologists and primary care providers to ensure consistent, high-quality monitoring.

People in early-stage Type 1 diabetes (particularly those with multiple autoantibodies) who are interested should be offered opportunities to participate in clinical trials or to receive approved therapies designed to slow disease progression.

Before broad screening programs can be rolled out successfully, the appropriate infrastructure must be in place. This includes training healthcare providers to recognize and monitor people identified through screening, establishing clear communication pathways between specialists and primary care doctors, and ensuring that people have access to approved therapies and trial participation when indicated.

The consensus guidance recognizes that screening programs, once fully implemented, will identify significant numbers of children and adults with autoantibodies who need ongoing monitoring and care. Getting the systems right from the start is essential to turning the benefits of early detection into real improvements in outcomes.

Origin: medscape.com (News report). Evidence: News report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.